Article Text

Download PDFPDF

2022-RA-824-ESGO Human papillomavirus in vulvar carcinoma patients in Norway: its prognostic role and changes in prevalence and genotype distribution in two time periods, 1970–75 and 2000–05
Free
  1. Christin Julia Meltzer-Gunnes1,
  2. Agnes Kathrine Lie2,
  3. Milada Cvancarova Småstuen3,
  4. Christine Genevieve Monceyron Jonassen4 and
  5. Ingvild Vistad5,6
  1. 1Department of Gynaecology and Obstetrics, Sørlandet Hospital, Kristiansand, Norway
  2. 2Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
  3. 3University of Oslo, Oslo, Norway
  4. 4Østfold Hospital Kalnes, Grålum, Norway
  5. 5Sørlandet Hospital, Kristiansand, Norway
  6. 6University of Bergen, Bergen, Norway

Abstract

Introduction/Background Approximately 25–43% of vulvar squamous cell carcinomas (VSCC) are associated with human papillomavirus (HPV). They occur in younger women, are often of warty and basaloid histology and show a better prognosis than non-HPV cancers. The predominant genotypes are HPV 16, 33 and 18. VSCC incidence rates among women younger than 50–60 years are on the rise, partly explained by increasing exposure to HPV. However, studies on HPV-prevalence in VSCC over time are lacking. Thus, our aim was to compare HPV-prevalence and genotype distribution in Norwegian VSCC cases from 1970–75 and 2000–05 and investigate a possible prognostic role of HPV-infection.

Methodology All cases of VSCC from 1970–75 (N=153) and 2000–05 (N=199) were extracted from the Cancer Registry of Norway (N=352). Formalin-fixed, paraffin-embedded tissue blocks were retrieved and DNA was extracted. For 282 cases, HPV-DNA analysis was successfully performed. All samples were tested for 19 different genotypes, using real-time TaqMan PCR. Overall survival rates were calculated using the Kaplan Meier method. Multivariable Cox regression analysis was performed to estimate hazard ratios adjusted for age at diagnosis, FIGO stage and diagnostic period.

Results The percentage of HPV-positive cases increased significantly from 23.8% in 1970–75 to 35.3% in 2000–05 (p=0.037). The predominant genotypes detected were HPV 16 (73%), 33 (21%) and 18 (6%) in both periods. HPV-status was an independent prognostic factor with HPV-positive tumours being associated with a better prognosis, HR=0.65, 95%CI [0.48; 0.86], p=0.003. However, when adjusted for age at diagnosis, FIGO stage and diagnostic period, only higher FIGO stage remained significantly associated with higher mortality.

Abstract 2022-RA-824-ESGO Figure 1

Conclusion The percentage of HPV-positive VSCCs has increased from 1970–75 until 2000–05. The predominant genotypes are HPV 16, 33 and 18 and have not changed during the last decades. HPV-positive tumours were associated with better survival.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.